Repligen (RGEN) to Release Quarterly Earnings on Thursday

Repligen (NASDAQ:RGEN) is scheduled to issue its quarterly earnings data before the market opens on Thursday, February 22nd. Analysts expect the company to announce earnings of $0.12 per share for the quarter.

Shares of Repligen (RGEN) opened at $32.99 on Thursday. The stock has a market capitalization of $1,391.91, a P/E ratio of 55.92, a PEG ratio of 1.79 and a beta of 0.91. Repligen has a 1 year low of $29.56 and a 1 year high of $46.81.

Several analysts recently commented on RGEN shares. BidaskClub raised Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Citigroup started coverage on Repligen in a research note on Friday, December 8th. They issued a “buy” rating and a $45.00 price target on the stock. CL King started coverage on Repligen in a research note on Monday, November 13th. They issued a “buy” rating and a $41.00 price target on the stock. TheStreet lowered Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Finally, Zacks Investment Research raised Repligen from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $44.38.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at $1,291,818.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Anthony Hunt sold 8,970 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the completion of the transaction, the chief executive officer now directly owns 83,613 shares in the company, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/15/repligen-rgen-to-release-quarterly-earnings-on-thursday.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply